A study led by the National Cardiovascular Center in Japan has explored the potential benefits of dapagliflozin, a medication used to treat type 2 diabetes, in patients with chronic heart failure and diabetes.
The study aimed to investigate whether dapagliflozin could reduce urinary albumin excretion, a marker of kidney damage, and lower the occurrence of cardiovascular events in these patients.
The study involved 294 participants from 18 facilities in Japan and was conducted over two years. It was designed as a multicenter, randomized, open-label trial with a standard-treatment control group.
While the recommended dose of dapagliflozin for heart failure is 10 mg, the study administered either 5 mg or 10 mg of the medication.
Key Findings
While dapagliflozin did not demonstrate a significant reduction in urinary albumin excretion, which was the primary endpoint, it did show promise in reducing cardiovascular events.
The secondary endpoint, which measured cardiovascular events (including cardiovascular death, hospitalization for cardiovascular events, and additional heart failure medication), was lower in the dapagliflozin group compared to the standard treatment group.
Significance of the Study
This study marks the first report suggesting that dapagliflozin, particularly at a 5 mg dose, can effectively reduce cardiovascular events in patients dealing with chronic heart failure and type 2 diabetes.
These findings have the potential to inform treatment strategies for individuals with type 2 diabetes and chronic heart failure, offering valuable insights for clinical practice.
The study was published in the journal eClinicalMedicine, contributing to our understanding of how dapagliflozin may benefit individuals with both heart failure and diabetes.
If you care about diabetes, please read studies about This drug combo can treat type 2 diabetes in the long run effectively and findings of Eating fewer than 3 meals a day may help reduce risk of type 2 diabetes and obesity.
For more information about diabetes, please see recent studies about bone drug that could lower risk of type 2 diabetes, and results showing eating more eggs linked to higher risk of type 2 diabetes.
The research findings can be found in eClinicalMedicine.
Copyright © 2023 Knowridge Science Report. All rights reserved.
